Expression of the CXC subfamily chemokines (CXCL9, CXCL10, and CXCL13) and of the CC subfamily chemokine CCL18 was consistently found to be higher in bladder cancer patients in the CLR-high group than in the patients in CLR-low group. This evidence concerns the gene DCLK3 and urinary bladder carcinoma.